Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00329121




Registration number
NCT00329121
Ethics application status
Date submitted
22/05/2006
Date registered
24/05/2006
Date last updated
19/01/2015

Titles & IDs
Public title
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In Situ
Scientific title
Multi-centre, Open-label Study to Determine the Safety and Efficacy of PEP005 0.05% Topical Gel in Patients With Cutaneous Squamous Cell Carcinoma In Situ (SCCIS, Bowen's Disease)
Secondary ID [1] 0 0
PEP005-008
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Squamous Cell 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Cervical (cervix)
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety
Timepoint [1] 0 0
Secondary outcome [1] 0 0
Efficacy
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
1. Male patients, at least 18 years of age.
2. Post-menopausal female patients, at least 18 years of age, i.e. no menses for at least 12 consecutive months, or without a uterus.
3. A primary, clinically diagnosed and histologically confirmed SCCIS lesion with the histological diagnosis being made within 90 days of the screening visit.
4. Longest diameter of the SCCIS lesion between 5 mm and 20 mm.
5. Ability to follow study instructions and likely to complete all study requirements.
6. Written informed consent has been obtained.
7. Written consent for tissue from the biopsy of the histologically confirmed SCCIS lesion to be examined and stored by the central dermatopathologist has been obtained.
8. Agreement from the patient to allow photographs of the selected SCCIS treatment area (including the face) to be used as part of the study data package.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Females of childbearing potential (a female is considered of childbearing potential unless she is post-menopausal, i.e. no menses for at least 12 consecutive months, or is without a uterus).
2. Location of the selected SCCIS lesion:

1. within 5 cm of an incompletely healed wound
2. within 2 cm of an eye, nose, or ear
3. within 1 cm of a scar
4. on the scalp, digits, lips, hands, feet, or ano-genital region
3. SCCIS lesions that have atypical clinical appearance, e.g. hypertrophic or hyperkeratotic or pigmented or ulcerated.
4. Histological evidence of nodular basal cell carcinoma (nBCC), superficial basal cell carcinoma (sBCC) or invasive squamous cell carcinoma (SCC) of the SCCIS in the biopsy sample.
5. Presence of suspected basal cell carcinoma (BCC) or invasive squamous cell carcinoma (SCC) within 2 cm of the selected SCCIS lesion.
6. Presence of known or suspected metastatic disease.
7. History or evidence of skin conditions other than SCCIS that would interfere with evaluation of the study medication (e.g. eczema, unstable psoriasis, xeroderma pigmentosa).
8. Known sensitivity to any of the ingredients in the study medication.
9. A cosmetic or therapeutic procedure (e.g. use of liquid nitrogen, surgical excision, curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing)

1. of the selected SCCIS lesion at any time; or
2. within 2 cm of the selected SCCIS lesion during the 4 weeks prior to screening visit; or
3. anticipated treatment within 10 cm of the selected SCCIS lesion during the study.
10. Treatment with 5-fluorouracil, imiquimod, diclofenac, or masoprocol

* of the selected SCCIS lesion at any time; or
* within 2 cm of the selected SCCIS lesion during the 6 months prior to study entry; or
* anywhere during the 4 weeks prior to study entry; or
* anticipated treatment anywhere during the study.
11. Treatment with photodynamic therapy

* of the selected SCCIS lesion at any time; or
* within 10 cm of the selected SCCIS lesion during the 6 months prior to study entry; or
* anticipated treatment within 10 cm of the selected SCCIS lesion during the study.
12. Treatment with ionising radiation

* of the selected SCCIS lesion at any time; or
* within 2 cm of the selected SCCIS lesion prior to study entry; or
* anticipated treatment anywhere during the study.
13. Treatment with other immunomodulators (e.g. vinblastine, podophyllin, colhamin, camptothecin), cytotoxic drugs (e.g. cyclophosphamide, azathioprine, chlorambucil, nitrogen mustard, methotrexate), or interferon/interferon inducers (other than imiquimod)

* within 4 weeks prior to study entry; or
* anticipated treatment during the study.
14. Use of acid-containing therapeutic products (e.g. salicylic acids or fruit acids, such as a and ß hydroxy acids and glycolic acids), topical retinoids, or light chemical peels

* of the selected SCCIS lesion at any time; or
* within 2 cm of the selected SCCIS lesion during the 4 weeks prior to study entry; or
* anticipated treatment within 2 cm of the selected SCCIS lesion during the study.
15. Treatment with psoralen plus ultraviolet light A [UVA] (PUVA) or use of ultraviolet light B (UVB) therapy

* of the selected SCCIS lesion at any time; or
* anywhere during the 6 months prior to study entry; or
* anticipated treatment anywhere during the study.
16. Use of systemic retinoids (e.g. isotretinoin, acitretin, bexarotene)

* during the 6 months prior to study entry; or
* anticipated treatment during the study.
17. Anticipated excessive or prolonged exposure to ultraviolet light (e.g. sunlight, tanning beds) or use of topical salves or topical steroids to the selected SCCIS lesion during the study.
18. SCCIS lesions requiring Mohs micrographic surgery.
19. Anticipated need for inpatient hospitalisation or inpatient surgery during the study.
20. Concurrent disease that suppresses the immune system (e.g. HIV, hepatitis) or uncontrolled systemic disease (e.g. uncontrolled hypertension, poorly controlled diabetes).
21. Use of medications that suppress the immune system (e.g. cyclosporine, prednisone, methotrexate, alefacept, infliximab)

* within 4 weeks prior to study entry; or
* anticipated treatment during the study.
22. Current evidence of chronic alcohol or drug abuse.
23. Current enrolment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.
24. Entry into another investigational drug or device study while enrolled in this study.
25. A condition or situation which in the Investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.
26. Selected SCCIS lesion within 5 cm of an area previously treated with PEP005.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/05/2006
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2006
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Southderm Pty Ltd - Kogarah
Recruitment hospital [2] 0 0
The Skin Centre - Benowa
Recruitment hospital [3] 0 0
Siller Medical - Brisbane
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
4217 - Benowa
Recruitment postcode(s) [3] 0 0
4000 - Brisbane

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Peplin
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine whether the topical application of PEP005 is safe and effective for the treatment of cutaneous squamous cell carcinoma in situ (SCCIS, Bowen's disease).
Trial website
https://clinicaltrials.gov/study/NCT00329121
Trial related presentations / publications
Rosen R, Freeman M, Siller G, Zibert JR, Katsamas J, Knudsen KM, Spelman L. Ingenol mebutate 0.05% gel reduces cancer cells in squamous cell carcinoma in situ and shows marginal effect in seborrheic keratosis. JDDG J German Soc Dermatol 2013; 11(Suppl. 7): 22
Public notes

Contacts
Principal investigator
Name 0 0
Robert Rosen, Dr.
Address 0 0
Southderm Pty Ltd
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00329121